Summary
The response includes a correct, label-supported general indication for teriflunomide/AUBAGIO (relapsing forms of MS in adults) but makes multiple claims about coupon/savings availability and pharmacy ability to “immediately” verify coupon pricing, none of which are supported by the provided FDA label excerpts and are therefore unsupported relative to the supplied prescribing information.
Category Scores
Accurate Statements
Teriflunomide is a prescription medicine used for multiple sclerosis.
Supported in the provided label excerpt: AUBAGIO (teriflunomide) is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults (Section 1 INDICATIONS AND USAGE).
Unsupported Statements
Coupon availability for teriflunomide depends on the country and on the manufacturer/seller of the specific teriflunomide brand in the region.
No information about coupons, savings programs, or country/manufacturer-dependent availability is present in the supplied prescribing information excerpts.
Some teriflunomide brands have savings cards in some markets.
Not supported by the supplied prescribing information excerpts.
Savings cards may not be available for every insurance situation.
Not supported by the supplied prescribing information excerpts.
In some programs, coupons may not be usable with government insurance (Medicaid/Medicare).
Not supported by the supplied prescribing information excerpts.
Some coupons only apply to commercial insurance plans.
Not supported by the supplied prescribing information excerpts.
Savings programs may require the patient to meet eligibility criteria.
Not supported by the supplied prescribing information excerpts.
The pharmacy can tell immediately whether a coupon will price down for a specific situation.
Not supported by the supplied prescribing information excerpts.
Contradictions
Important Omissions
No label-relevant prescribing content (e.g., dosage, contraindications, boxed warnings/precautions such as hepatotoxicity and embryofetal toxicity, or monitoring instructions) is addressed in the response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-aligned claim is general indication. Coupon-related statements are not label-supported but also do not directly alter dosing/contraindications within the evaluated excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims about coupon/savings-card availability and pharmacy/insurance behavior are not supported by the supplied FDA label excerpts.
Suggested Improvement
Limit the response to FDA label-supported information (e.g., indication, contraindications, hepatotoxicity monitoring, and embryofetal toxicity precautions) or clearly separate non-label reimbursement/coupon information from label-based content.